Carl H June

List of Publications by Year in Descending Order

310 papers	59,710 citations	116 h-index	243 g-index
333 ext. papers	73,468 ext. citations	14.8 avg, IF	8.34 L-index

#	Paper	IF	Citations
310	CAR T cells produced in vivo to treat cardiac injury.. *Science*, **2022**, 375, 91-96	33.3	44
309	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. *Nature*, **2022**,	50.4	30
308	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.. *Nature Medicine*, **2022**,	50.5	13
307	Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers.. *Immunity*, **2022**, 55, 557-574.e7	32.3	0
306	Next-Generation CAR T-cell Therapies.. *Cancer Discovery*, **2022**, OF1-OF14	24.4	1
305	Engineered cellular immunotherapies in cancer and beyond.. *Nature Medicine*, **2022**, 28, 678-689	50.5	6
304	Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. *Current Opinion in Immunology*, **2021**, 74, 76-84	7.8	2
303	An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell*, **2021**, 184, 6081-6100.e26	56.2	15
302	Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. *Clinical Cancer Research*, **2021**,	12.9	2
301	Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. *Nano Letters*, **2021**,	11.5	3
300	CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch. *Leukemia*, **2021**, 35, 3309-3313	10.7	1
299	Production of Human CRISPR-Engineered CAR-T Cells. *Journal of Visualized Experiments*, **2021**,	1.6	3
298	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *British Journal of Haematology*, **2021**, 193, 851-855	4.5	0
297	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. *Nature Medicine*, **2021**, 27, 842-850	50.5	22
296	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
295	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. *Frontiers in Oncology*, **2021**, 11, 669071	5.3	8
294	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells **2021**, 9,		6

293	Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. *Molecular Therapy*, **2021**, 29, 626-635	11.7	0
292	Nanomaterials for T-cell cancer immunotherapy. *Nature Nanotechnology*, **2021**, 16, 25-36	28.7	57
291	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
290	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia **2021**, 9,		4
289	The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. *Cell*, **2021**, 184, 4981-4995.e14	56.2	18
288	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. *Cells*, **2021**, 10,	7.9	1
287	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2021**, 39, 3044-3055	2.2	23
286	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6580-6590	12.9	1
285	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. *Lancet Haematology,the*, **2021**, 8, e711-e722	14.6	6
284	Costimulation of CR and TLR7/8 promotes V2 T-cell antitumor activity by modulating mTOR pathway and APC function. **2021**, 9,		3
283	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. *Blood*, **2020**, 135, 505-509	2.2	15
282	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. *Blood*, **2020**, 136, 1980-1983	2.2	7
281	Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nature Biotechnology*, **2020**, 38, 947-953	44.5	290
280	4-1BB costimulation promotes CAR T cell survival through noncanonical NF-B signaling. *Science Signaling*, **2020**, 13,	8.8	44
279	Cancer immunotherapy comes of age and looks for maturity. *Nature Communications*, **2020**, 11, 3325	17.4	41
278	CRISPR-engineered T cells in patients with refractory cancer. *Science*, **2020**, 367,	33.3	448
277	Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. *Nano Letters*, **2020**, 20, 1578-1589	11.5	125
276	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. *Cancer Discovery*, **2020**, 10, 552-567	24.4	79

275	A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. *JCI Insight*, **2020**, 5,	9.9	17
274	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *Journal of Clinical Investigation*, **2020**, 130, 673-685	15.9	45
273	Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. *Journal of Clinical Investigation*, **2020**, 130, 3087-3097	15.9	66
272	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. *Blood*, **2020**, 136, 30-32	2.2	1
271	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 415-422	2.2	80
270	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. *Cell*, **2020**, 183, 126-142.e17	56.2	101
269	Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. *Journal of Clinical Pharmacology*, **2020**, 60 Suppl 1, S147-S159	2.9	10
268	Cytokine Storm. *New England Journal of Medicine*, **2020**, 383, 2255-2273	59.2	757
267	Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 595-606	6.4	14
266	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Molecular Therapy*, **2020**, 28, 2367-2378	11.7	13
265	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. *Blood Advances*, **2020**, 4, 5174-5183	7.8	10
264	Cytokine release syndrome in severe COVID-19. *Science*, **2020**, 368, 473-474	33.3	1073
263	Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. *Cancer Discovery*, **2020**, 10, 775-778	24.4	24
262	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 2862-2871	2.2	45
261	Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. *Blood*, **2020**, 135, 713-723	2.2	67
260	Targeting cardiac fibrosis with engineered T cells. *Nature*, **2019**, 573, 430-433	50.4	185
259	iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. *Genome Biology*, **2019**, 20, 14	18.3	20
258	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy. *Blood*, **2019**, 134, 44-58	2.2	69

257	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 285-295	4.5	42
256	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell*, **2019**, 178, 933-948.e14	56.2	141
255	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Molecular Therapy*, **2019**, 27, 1919-1929	11.7	101
254	Boosting engineered T cells. *Science*, **2019**, 365, 119-120	33.3	8
253	Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. *JCI Insight*, **2019**, 4,	9.9	10
252	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *Journal of Clinical Investigation*, **2019**, 129, 2210-2221	15.9	312
251	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. *Blood*, **2019**, 134, 49-49	2.2	7
250	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. *Blood*, **2019**, 134, 1909-1909	2.2	3
249	Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications. *Blood*, **2019**, 134, 594-594	2.2	7
248	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 1863-1863	2.2	13
247	A phase I clinical trial of PSMA-directed/TGF□nsensitive CAR-T cells in metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, TPS347-TPS347	2.2	22
246	A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 681-681	2.2	2
245	Engineered T Cell Therapies from a Drug Development Viewpoint. *Engineering*, **2019**, 5, 140-149	9.7	7
244	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. *Blood Advances*, **2019**, 3, 2812-2815	7.8	61
243	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. *Blood Advances*, **2019**, 3, 3539-3549	7.8	76
242	Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. *British Journal of Cancer*, **2019**, 120, 54-56	8.7	15
241	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. *Clinical Cancer Research*, **2019**, 25, 2042-2048	12.9	43
240	Delivery technologies for cancer immunotherapy. *Nature Reviews Drug Discovery*, **2019**, 18, 175-196	64.1	823

239	Emerging Cellular Therapies for Cancer. *Annual Review of Immunology*, **2019**, 37, 145-171	34.7	175
238	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. *Neuro-Oncology*, **2018**, 20, 1429-1438	1	114
237	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. *Science Translational Medicine*, **2018**, 10,	17.5	205
236	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *New England Journal of Medicine*, **2018**, 378, 439-448	59.2	2275
235	Glycan-directed CAR-T cells. *Glycobiology*, **2018**, 28, 656-669	5.8	49
234	The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. *Scientific Reports*, **2018**, 8, 6289	4.9	77
233	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*, **2018**, 24, 563-571	50.5	649
232	Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. *Cancer Immunology Research*, **2018**, 6, 605-616	12.5	143
231	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology*, **2018**, 155, 29-32	13.3	209
230	CAR T cell immunotherapy for human cancer. *Science*, **2018**, 359, 1361-1365	33.3	1163
229	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. *Molecular Therapy*, **2018**, 26, 280-288	11.7	53
228	Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. *Blood*, **2018**, 132, 1022-1026	2.2	38
227	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight*, **2018**, 3,	9.9	250
226	Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunology Research*, **2018**, 6, 1100-1109	12.5	105
225	Gut microbiota modulates adoptive cell therapy via CD8 dendritic cells and IL-12. *JCI Insight*, **2018**, 3,	9.9	70
224	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. *Blood*, **2018**, 132, 1886-1886	2.2	14
223	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. *Blood*, **2018**, 132, 298-298	2.2	61
222	Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. *Blood*, **2018**, 132, 4198-4198	2.2	51

221	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. *Molecular Therapy*, **2018**, 26, 269-279	11.7	63
220	CAR T-Cell Therapies in Glioblastoma: A First Look. *Clinical Cancer Research*, **2018**, 24, 535-540	12.9	80
219	Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight*, **2018**, 3,	9.9	122
218	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI Insight*, **2018**, 3,	9.9	90
217	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance **2018**, 6, 137		120
216	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nature Medicine*, **2018**, 24, 1499-1503	50.5	286
215	Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. *Molecular Therapy - Oncolytics*, **2018**, 11, 20-38	6.4	70
214	CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. *Leukemia*, **2018**, 32, 2307-2315	10.7	51
213	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. *Cytotherapy*, **2018**, 20, 1415-1418	4.8	29
212	Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. *Frontiers in Immunology*, **2018**, 9, 2486	8.4	109
211	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. *Clinical Cancer Research*, **2018**, 24, 6175-6184	12.9	98
210	Dominant-Negative TGF-βReceptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Molecular Therapy*, **2018**, 26, 1855-1866	11.7	247
209	Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. *Molecular Therapy*, **2018**, 26, 1401-1403	11.7	11
208	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*, **2018**, 558, 307-312	42.4	362
207	Chimeric Antigen Receptor Therapy. *New England Journal of Medicine*, **2018**, 379, 64-73	59.2	880
206	Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. *Cancer Research*, **2017**, 77, 2052-2063	10.1	94
205	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood*, **2017**, 129, 2395-2407	2.2	116
204	The Principles of Engineering Immune Cells to Treat Cancer. *Cell*, **2017**, 168, 724-740	56.2	583

203	Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. *Methods in Molecular Biology*, **2017**, 1584, 443-450	1.4	1
202	Is autoimmunity the Achilles' heel of cancer immunotherapy?. *Nature Medicine*, **2017**, 23, 540-547	50.5	257
201	Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. *Protein and Cell*, **2017**, 8, 514-526	7.2	10
200	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer Discovery*, **2017**, 7, 1154-1167	24.4	98
199	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. *Critical Care Medicine*, **2017**, 45, e124-e131	1.4	261
198	Driving gene-engineered T cell immunotherapy of cancer. *Cell Research*, **2017**, 27, 38-58	24.7	173
197	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood*, **2017**, 129, 1039-1041	2.2	285
196	Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. *Blood*, **2017**, 130, 2569-2572	2.2	65
195	Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. *Cell Stem Cell*, **2017**, 21, 427-430	18	21
194	Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. *Cell Reports*, **2017**, 20, 3025-3033	10.6	205
193	Immunotherapy for Breast Cancer: Current and Future Strategies. *Current Surgery Reports*, **2017**, 5, 1	0.5	19
192	Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. *Current Hematologic Malignancy Reports*, **2017**, 12, 522-529	4.4	48
191	A versatile system for rapid multiplex genome-edited CAR T cell generation. *Oncotarget*, **2017**, 8, 17002-17011	5.3	237
190	Immunotherapy for Brain Tumors. *Journal of Clinical Oncology*, **2017**, 35, 2450-2456	2.2	73
189	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. *Blood*, **2017**, 130, 2317-2325	2.2	180
188	Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. *Methods in Molecular Biology*, **2017**, 1633, 267-276	1.4	6
187	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Science Translational Medicine*, **2017**, 9,	17.5	697
186	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *New England Journal of Medicine*, **2017**, 377, 2545-2554	59.2	951

185	Human CD26 T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. *Nature Communications*, **2017**, 8, 1961	17.4	35
184	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunology Research*, **2017**, 5, 1152-1161	12.5	181
183	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer **2017**, 5, 22		136
182	Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clinical Cancer Research*, **2017**, 23, 2255-2266	12.9	495
181	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy*, **2017**, 19, 250-262	4.8	32
180	Ibrutinib treatment improves T cell number and function in CLL patients. *Journal of Clinical Investigation*, **2017**, 127, 3052-3064	15.9	197
179	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. *Blood*, **2017**, 130, 807-807	2.2	4
178	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. *Current Hematologic Malignancy Reports*, **2016**, 11, 368-84	4.4	50
177	Engineered T cells: the promise and challenges of cancer immunotherapy. *Nature Reviews Cancer*, **2016**, 16, 566-81	31.3	662
176	Adoptive Cellular Therapy With Synthetic T Cells as an Instant Vaccine for Cancer and Immunity **2016**, 581-596		1
175	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. *Blood*, **2016**, 128, 360-70	2.2	143
174	Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. *Immunity*, **2016**, 45, 947-948	32.3	20
173	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. *Immunity*, **2016**, 44, 1444-54	32.3	338
172	Remote Controlled CARs: Towards a Safer Therapy for Leukemia. *Cancer Immunology Research*, **2016**, 4, 643	12.5	5
171	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials **2016**, 4, 15		47
170	Phosphatidylinositol 3-Kinase p110 Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. *Journal of Immunology*, **2016**, 196, 1186-98	5.3	23
169	Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. *OncoImmunology*, **2016**, 5, e1062210	7.2	4
168	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. *Cancer Research*, **2016**, 76, 1578-90	10.1	308

167	Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. *Immunity*, **2016**, 44, 380-90	32.3	515
166	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. *Clinical Cancer Research*, **2016**, 22, 2684-96	12.9	108
165	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. *OncoImmunology*, **2016**, 5, e1040216	7.2	28
164	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. *Blood*, **2016**, 128, 1147-1147	2.2	53
163	Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia. *Blood*, **2016**, 128, 220-220	2.2	4
162	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. *Blood*, **2016**, 128, 2801-2801	2.2	46
161	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. *Blood*, **2016**, 128, 281-281	2.2	11
160	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 57-57	2.2	14
159	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. *Blood*, **2016**, 128, 5702-5702	2.2	23
158	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. *Blood*, **2016**, 128, 652-652	2.2	24
157	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. *Blood*, **2016**, 128, 766-766	2.2	9
156	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. *Blood*, **2016**, 128, 974-974	2.2	27
155	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. *PLoS Pathogens*, **2016**, 12, e1005983	7.6	26
154	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?. *Pathogens and Immunity*, **2016**, 1, 154-164	4.9	28
153	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *Journal of Clinical Investigation*, **2016**, 126, 3814-3826	15.9	352
152	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. *American Journal of Hematology*, **2016**, 91, 453-60	7.1	6
151	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *Journal of Immunological Methods*, **2016**, 434, 1-8	2.5	108
150	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. *Cancer Discovery*, **2016**, 6, 664-79	24.4	603

149	Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. *Clinical Cancer Research*, **2016**, 22, 1875-84	12.9	182
148	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood*, **2016**, 127, 1044-51	2.2	251
147	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
146	Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. *Journal of the American Academy of Dermatology*, **2016**, 75, 1054-1057	4.5	12
145	Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation **2016**, 826-838		1
144	Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. *Molecular Therapy* , **2016**, 24, 1173-7	11.7	1
143	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nature Medicine*, **2015**, 21, 914-921	50.5	543
142	Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *Journal of Immunology*, **2015**, 195, 755-61	5.3	124
141	Adoptive cellular therapy: a race to the finish line. *Science Translational Medicine*, **2015**, 7, 280ps7	17.5	252
140	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. *Clinical Cancer Research*, **2015**, 21, 2840-50	12.9	42
139	Measurement of intracellular ions by flow cytometry. *Current Protocols in Cytometry*, **2015**, 72, 9.8.1-9.8.21	3.6	7
138	T cell engineering as therapy for cancer and HIV: our synthetic future. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370, 20140374	5.8	20
137	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translational Medicine*, **2015**, 7, 303ra139	17.5	1071
136	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 1040-7	59.2	417
135	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. *Cancer Research*, **2015**, 75, 3596-607	10.1	298
134	Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews*, **2015**, 263, 68-89	11.3	237
133	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. *Neuro-Oncology*, **2015**, 17, v110.4-v111	1	9
132	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Science Translational Medicine*, **2015**, 7, 275ra22	17.5	301

131	Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task. *Cancer Immunology Research*, **2015**, 3, 470-2	12.5	2
130	Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. *Cancer Research*, **2015**, 75, 2800-2810	10.1	247
129	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. *Cancer Immunology Research*, **2015**, 3, 356-67	12.5	181
128	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. *Blood*, **2015**, 126, 3769-3769	2.2	34
127	Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia. *Blood*, **2015**, 126, 4280-4280	2.2	12
126	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. *Blood*, **2015**, 126, 683-683	2.2	15
125	Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.. *Journal of Clinical Oncology*, **2015**, 33, 3007-3007	2.2	28
124	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. *Cytotherapy*, **2014**, 16, 619-30	4.8	74
123	Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *New England Journal of Medicine*, **2014**, 370, 901-10	59.2	1018
122	Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer Immunology Research*, **2014**, 2, 154-66	12.5	307
121	Chimeric antigen receptor therapy for cancer. *Annual Review of Medicine*, **2014**, 65, 333-47	17.4	275
120	Toward synthetic biology with engineered T cells: a long journey just begun. *Human Gene Therapy*, **2014**, 25, 779-84	4.8	6
119	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. *Blood*, **2014**, 123, 61-9	2.2	116
118	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunology Research*, **2014**, 2, 112-20	12.5	558
117	CARTs on the road for myeloma. *Clinical Cancer Research*, **2014**, 20, 3899-901	12.9	13
116	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunology Research*, **2014**, 2, 1059-70	12.5	52
115	Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, **2014**, 371, 1507-17	59.2	3305
114	Engineered T cells for cancer therapy. *Cancer Immunology, Immunotherapy*, **2014**, 63, 969-75	7.4	90

113	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. *Blood*, **2014**, 123, 2343-54	2.2	309
112	Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. *Clinical Cancer Research*, **2014**, 20, 4262-73	12.9	256
111	Antibody-modified T cells: CARs take the front seat for hematologic malignancies. *Blood*, **2014**, 123, 2625-35	2.2	476
110	ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. *Blood*, **2014**, 124, 1070-80	2.2	213
109	Changing the mindset in life sciences toward translation: a consensus. *Science Translational Medicine*, **2014**, 6, 264cm12	17.5	31
108	Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. *Clinical Cancer Research*, **2014**, 20, 1355-65	12.9	104
107	Adoptive immunotherapy for cancer or viruses. *Annual Review of Immunology*, **2014**, 32, 189-225	34.7	201
106	Engineering T cells for cancer: our synthetic future. *Immunological Reviews*, **2014**, 257, 7-13	11.3	38
105	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. *Blood*, **2014**, 124, 1982-1982	2.2	32
104	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. *Blood*, **2014**, 124, 380-380	2.2	12
103	Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia. *Blood*, **2014**, 124, 4803-4803	2.2	
102	Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells. *Blood*, **2014**, 124, 551-551	2.2	
101	Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. *Immunity*, **2013**, 39, 49-60	32.3	360
100	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. *Cancer Immunology, Immunotherapy*, **2013**, 62, 773-85	7.4	69
99	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. *Human Gene Therapy*, **2013**, 24, 717-27	4.8	84
98	Perspective: assembly line immunotherapy. *Nature*, **2013**, 498, S17	50.4	34
97	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts **2013**, 1, 21		61
96	Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. *Biology of Blood and Marrow Transplantation*, **2013**, 19, S2-5	4.7	27

95	Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1094-101	4.7	21
94	Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. *Human Gene Therapy*, **2013**, 24, 245-58	4.8	99
93	IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. *Journal of Translational Medicine*, **2013**, 11, 37	8.5	60
92	Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *New England Journal of Medicine*, **2013**, 368, 1509-1518	59.2	2406
91	Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. *Cancer Immunology Research*, **2013**, 1, 43-53	12.5	228
90	Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. *Cancer Research*, **2013**, 73, 3566-77	10.1	88
89	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	376
88	Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Science Translational Medicine*, **2013**, 5, 197ra103	17.5	441
87	Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. *Human Gene Therapy*, **2013**, 24, 27-37	4.8	15
86	Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. *Blood*, **2013**, 121, 1524-33	2.2	76
85	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood*, **2013**, 122, 863-71	2.2	750
84	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. *Blood*, **2013**, 122, 4162-4162	2.2	13
83	T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL. *Blood*, **2013**, 122, 67-67	2.2	16
82	Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. *Blood*, **2013**, 122, 873-873	2.2	12
81	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	94
80	Tumor immunotherapy **2013**, 935-945		
79	Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. *Clinical Cancer Research*, **2012**, 18, 6732-41	12.9	33
78	Blocking HIV's attack. *Scientific American*, **2012**, 306, 54-9	0.5	9

77	T-cell therapy at the threshold. *Nature Biotechnology*, **2012**, 30, 611-4	44.5	51
76	Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science Translational Medicine*, **2012**, 4, 132ra53	17.5	456
75	Novel cell and gene therapies for HIV. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2,	5.4	48
74	A human memory T cell subset with stem cell-like properties. *Nature Medicine*, **2011**, 17, 1290-7	50.5	1153
73	Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Science Translational Medicine*, **2011**, 3, 83ra41	17.5	272
72	Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *New England Journal of Medicine*, **2011**, 365, 725-33	59.2	2502
71	Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. *Blood*, **2011**, 117, 63-71	2.2	35
70	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. *Blood*, **2011**, 118, e112-7	2.2	39
69	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. *Journal of Translational Medicine*, **2011**, 9, 131	8.5	46
68	Adoptive cellular therapy. *Current Topics in Microbiology and Immunology*, **2011**, 344, 149-72	3.3	18
67	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. *Blood*, **2011**, 117, 788-97	2.2	129
66	T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Science Translational Medicine*, **2011**, 3, 95ra73	17.5	1656
65	Treatment of advanced leukemia in mice with mRNA engineered T cells. *Human Gene Therapy*, **2011** , 22, 1575-86	4.8	149
64	Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. *Cancer Research*, **2011**, 71, 3175-81	10.1	56
63	In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). *Cancer Research*, **2011**, 71, 4617-27	10.1	210
62	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. *Clinical Cancer Research*, **2011**, 17, 4719-30	12.9	363
61	Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. *PLoS Pathogens*, **2011**, 7, e1002020	7.6	118
60	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. *Blood*, **2011**, 117, 1061-70	2.2	812

59	Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2855-2855	2.2	
58	A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies. *Blood*, **2011**, 118, 3032-3032	2.2	
57	Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Research*, **2010**, 70, 9053-61	10.1	334
56	The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. *Science Translational Medicine*, **2010**, 2, 55ra78	17.5	185
55	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. *Blood*, **2010**, 116, 2140-2140	2.2	1
54	T-Rapa Cell Clinical Products Contain a Balance of Minimally Differentiated Th2/Th1 Effector Cells Depleted of Treg Cells. *Blood*, **2010**, 116, 352-352	2.2	2
53	Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy. *Blood*, **2010**, 116, 521-521	2.2	1
52	Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2010**, 116, 683-683	2.2	
51	Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. *Clinical Cancer Research*, **2009**, 15, 4499-507	12.9	81
50	Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. *Molecular Therapy*, **2009**, 17, 844-50	11.7	122
49	Engineering lymphocyte subsets: tools, trials and tribulations. *Nature Reviews Immunology*, **2009**, 9, 704-16	36.5	156
48	Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunity*, **2009**, 30, 656-65	32.3	358
47	Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Molecular Therapy*, **2009**, 17, 1453-64	11.7	786
46	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3360-5	11.5	637
45	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. *Nature Biotechnology*, **2008**, 26, 808-16	44.5	812
44	Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nature Medicine*, **2008**, 14, 1390-5	50.5	204
43	CD28 costimulation is essential for human T regulatory expansion and function. *Journal of Immunology*, **2008**, 181, 2855-68	5.3	133
42	Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. *Molecular Therapy*, **2008**, 16, 580-9	11.7	112

41	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. *Journal of Immunology*, **2008**, 180, 5794-8	5.3	156
40	Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. *Clinical Cancer Research*, **2008**, 14, 3966-74	12.9	66
39	Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. *PLoS ONE*, **2008**, 3, e3289	3.7	40
38	Genetic engineering of T cells for adoptive immunotherapy. *Immunologic Research*, **2008**, 42, 166-81	4.3	53
37	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. *Immunologic Research*, **2008**, 42, 182-96	4.3	43
36	Genetic therapies against HIV. *Nature Biotechnology*, **2007**, 25, 1444-54	44.5	195
35	4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. *Journal of Immunology*, **2007**, 179, 4910-8	5.3	164
34	Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. *Molecular Therapy*, **2007**, 15, 981-8	11.7	206
33	Programming the next generation of dendritic cells. *Molecular Therapy*, **2007**, 15, 846-8	11.7	5
32	Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 1135-44	4.7	27
31	Principles of adoptive T cell cancer therapy. *Journal of Clinical Investigation*, **2007**, 117, 1204-12	15.9	197
30	Adoptive T cell therapy for cancer in the clinic. *Journal of Clinical Investigation*, **2007**, 117, 1466-76	15.9	400
29	Gene transfer in humans using a conditionally replicating lentiviral vector. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 17372-7	11.5	395
28	A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. *Blood*, **2006**, 107, 1325-31	2.2	190
27	Clinical application of expanded CD4+25+ cells. *Seminars in Immunology*, **2006**, 18, 78-88	10.7	83
26	Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. *Blood*, **2006**, 107, 483-91	2.2	85
25	Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. *Blood*, **2005**, 105, 750-8	2.2	256
24	Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. *Nature Medicine*, **2005**, 11, 1230-7	50.5	256

23	Stable Gene Transfer and Expression in Human Primary T-Cells by the Sleeping Beauty Transposon System.. *Blood*, **2005**, 106, 5539-5539	2.2	
22	Extensive replicative capacity of human central memory T cells. *Journal of Immunology*, **2004**, 172, 6675-83	5.3	40
21	SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *Journal of Immunology*, **2004**, 173, 945-54	5.3	793
20	Measurement of intracellular ions by flow cytometry. *Current Protocols in Immunology*, **2004**, Chapter 5, Unit 5.5	4	23
19	Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. *Blood*, **2003**, 102, 2004-13	2.2	169
18	A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. *Immunologic Research*, **2003**, 27, 341-56	4.3	26
17	Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. *Nature Medicine*, **2003**, 9, 619-24	50.5	256
16	CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. *Journal of Immunology*, **2003**, 171, 166-74	5.3	132
15	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nature Biotechnology*, **2002**, 20, 143-8	44.5	339
14	Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. *Nature Medicine*, **2002**, 8, 47-53	50.5	152
13	A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. *Molecular Therapy*, **2002**, 5, 788-97	11.7	222
12	A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. *Clinical Immunology*, **2002**, 105, 259-72	9	70
11	The CD28 signaling pathway regulates glucose metabolism. *Immunity*, **2002**, 16, 769-77	32.3	970
10	Prolonged survival and tissue trafficking following adoptive transfer of CD4 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus infected subjects. *Blood*, **2000**, 96, 785-793	2.2	305
9	Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. *Journal of Immunology*, **2000**, 165, 6908-14	5.3	38
8	Prolonged survival and tissue trafficking following adoptive transfer of CD4 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus infected subjects. *Blood*, **2000**, 96, 785-793	2.2	70
7	Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. *Stem Cells and Development*, **1998**, 7, 437-48		99
6	The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. *Seminars in Immunology*, **1998**, 10, 195-202	10.7	21

5	Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science*, **1997**, 276, 273-6	33.3	182
4	Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. *Immunological Reviews*, **1997**, 160, 43-54	11.3	165
3	Genetically Modified T Cells for Human Gene Therapy193-205		
2	CAR T Cells Secreting IL18 Augment Antitumor Immunity and Increase T Cell Proliferation and Costimulation		2
1	Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19		1